Another subtype of prostate cancer, known as amphicrine carcinoma (AMPC), expresses neuroendocrine markers in addition to luminal-lineage markers such as prostate-specific antigen (PSA) and AR18. This evidence concerns the gene KLK3 and Familial prostate cancer.